

# Holding(s) in Company

Released : 23 January 2024 7:00

RNS Number : 5916A  
Ovoca Bio PLC  
23 January 2024

**Ovoca Bio plc**

**("Ovoca" or the "Company")**

## **Holding(s) in Company**

Dublin, Ireland, January 23, 2024 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, received notification from Mr. Leonid Skoptsov on 16 January 2024 that, as of 17 October 2023, he holds an interest in 10,002,078 ordinary shares of nominal value €0.125 each, which represents 12.26%\* of the Company's issued share capital (excluding treasury shares). The Company also received notification from Mr. Alexandr Mogutov on 16 January 2024 that, as of 17 October 2023, he no longer has a notifiable interest in the Company's issued share capital (excluding treasury shares).

\*This percentage shareholding is based on a share in issue figure of 81,563,806 ordinary shares of nominal value €0.125 each. The Company also holds 6,895,000 ordinary shares in treasury, which do not carry voting rights.

**End**

For further information:

### **Ovoca Bio plc**

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

[info@ovocabio.com](mailto:info@ovocabio.com)

### **Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)**

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

### **About Ovoca Bio**

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing Orenetide (BP-101), a novel synthetic peptide administered through a nasal spray as a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

HOLFIFSRRLRIVFIS